KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance

Feng,Tongfu; Wang,Yan; Lang,Yan; Zhang,Yuanzhen

doi:10.3892/mmr.2017.6960

KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance

Authors:
- Tongfu Feng
- Yan Wang
- Yan Lang
- Yuanzhen Zhang
View Affiliations

Affiliations: Center of Reproductive Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Gynecology, Hubei Maternal and Children's Hospital, Wuhan, Hubei 430070, P.R. China
Published online on: July 12, 2017 https://doi.org/10.3892/mmr.2017.6960
Pages: 3573-3580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The authors initially performed reverse transcription‑quantitative polymerase chain reaction to determine the expression profile of KDM5A in ovarian cancer tissues and adjacent normal tissue. Compared with adjacent normal tissue, it was identified that KDM5A was highly expressed in ovarian cancer tissues. Moreover, human ovarian cell lines also confirmed that KDM5A was highly expressed in ovarian cancer. KDM5A was especially highly expressed in SKOV3/paclitaxel (PTX) cells, which are resistant to PTX. Previous studies demonstrated that chemoresistance in cancer cells facilitates epithelial‑to‑mesenchymal transition (EMT). Following this, whether KDM5A influenced EMT and metastasis was investigated. The expression of KDM5A and N‑cadherin were obviously higher in SKOV3/PTX cells than in SKOV3 cells. The expression of E‑cadherin was decreased and the expression of N‑cadherin was increased following ectopic expression of KDM5A, while the expression of E‑cadherin was increased and the expression of N‑cadherin was decreased following KDM5A depletion. Transwell and wound healing assays were used to explore the function of KMD5A in metastasis. The present results indicated that KDM5A facilitated EMT and metastasis in ovarian cells. Moreover, it was identified that P‑glycoprotein was increased while KDM5A was expressed ectopically in SKOV3 cells. Following fluorescence‑activated cell sorting flow cytometry analysis and CCK‑8 assay all revealed that KDM5A regulated the PTX sensitivity in SKOV3 and SKOV3/PTX cells. In brief, KDM5A is a crucial oncogene that is significantly upregulated in ovarian cancer. Its expression is closely correlated with cancer cell proliferation, EMT and metastasis. KDM5A suppresses ovarian cancer cell apoptosis under PTX treatment.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, et al: Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
3	DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
4	Di Francia R, De Lucia L, Di Paolo M, Di Martino S, Del Pup L, De Monaco A, Lleshi A and Berretta M: Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy. Eur Rev Med Pharmacol Sci. 19:4443–4454. 2015.PubMed/NCBI
5	Ding L, Wang XQ, Zhang J, Mu ZL, Zhou XX and Liu PS: Underlying mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in SKOV3 human ovarian cancer cells. Eur Rev Med Pharmacol Sci. 19:2084–2090. 2015.PubMed/NCBI
6	Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G and Bagnato A: miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 7:4009–4023. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 35:323–332. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M, Zhang H, Chen SF and Yao LQ: The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression. Eur Rev Med Pharmacol Sci. 19:818–824. 2015.PubMed/NCBI
9	Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and Sikic BI: Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol. 8:1231–1239. 2014. View Article : Google Scholar : PubMed/NCBI
10	Liu S, Sun J, Cai B, Xi X, Yang L, Zhang Z, Feng Y and Sun Y: NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Tumour Biol. 37:9671–9680. 2016. View Article : Google Scholar : PubMed/NCBI
11	Kouzarides T: Chromatin modifications and their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
12	Christensen J, Agger K, Cloos PA, Pasini D, Rose S, Sennels L, Rappsilber J, Hansen KH, Salcini AE and Helin K: RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 128:1063–1076. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lopez-Bigas N, Kisiel TA, Dewaal DC, Holmes KB, Volkert TL, Gupta S, Love J, Murray HL, Young RA and Benevolenskaya EV: Genome-wide analysis of the H3K4 histone demethylase RBP2 reveals a transcriptional program controlling differentiation. Mol Cell. 31:520–530. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA and Helin K: Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and polycomb-repressive complex 2. Genes Dev. 22:1345–1355. 2008. View Article : Google Scholar : PubMed/NCBI
15	Defeo-Jones D, Huang PS, Jones RE, Haskell KM, Vuocolo GA, Hanobik MG, Huber HE and Oliff A: Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature. 352:251–254. 1991. View Article : Google Scholar : PubMed/NCBI
16	Gildea JJ, Lopez R and Shearn A: A screen for new trithorax group genes identified little imaginal discs, the Drosophila melanogaster homologue of human retinoblastoma binding protein 2. Genetics. 156:645–663. 2000.PubMed/NCBI
17	Zeng J, Ge Z, Wang L, Li Q, Wang N, Björkholm M, Jia J and Xu D: The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology. 138:981–992. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, et al: Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci USA. 108:13379–13386. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL and Yang ZQ: Genomic amplification and a role in drug- resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 4:247–256. 2012.PubMed/NCBI
20	Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP and Yang ZQ: Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 28:4491–4500. 2009. View Article : Google Scholar : PubMed/NCBI
21	Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
22	Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, et al: The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 14:3418–3429. 2015. View Article : Google Scholar : PubMed/NCBI
23	Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
24	Cao H, Xu E, Liu H, Wan L and Lai M: Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
25	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
27	Grant S: Targeting histone demethylases in cancer therapy. Clin Cancer Res. 15:7111–7113. 2009. View Article : Google Scholar : PubMed/NCBI
28	Natoli G, Testa G and De Santa F: The future therapeutic potential of histone demethylases: A critical analysis. Curr Opin Drug Discov Devel. 12:607–615. 2009.PubMed/NCBI
29	Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI